Media & Investors
-
May 18, 2020Michael D. Price brings more than 25 years of experience in the pharmaceutical industry, including in the rare disease sector
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and...
-
May 14, 2020TEGSEDI is the first antisense medicine available to patients in Spain for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the...
-
May 13, 2020
OTTAWA, ON., - May 13, 2020 (CNW) – Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (NASDAQ: AKCA), today announced that it has concluded its negotiation with the...
-
May 7, 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief...
-
May 5, 2020Achieved First Quarter 2020 Global Net Product Revenues of $15 Million
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare...
-
Apr 21, 2020Webcast scheduled for Tuesday, May 5 at 4:30 p.m. Eastern Time
BOSTON, April 21, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on...
-
Mar 24, 2020
BOSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed
-
Mar 11, 2020
BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has...
-
Feb 28, 2020Company builds awareness of hATTR amyloidosis and FCS via social media campaign, and will host special event with employees, patients and caregivers
BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the company’s support for Rare...
-
Feb 26, 2020
BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to...
-
Feb 25, 2020Reported Full Year 2019 Global Net Product Revenues of $42 Million and Fourth Quarter 2019 Global Net Product Revenues of $14 Million
BOSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to...
-
Feb 18, 2020Webcast scheduled for Tuesday, February 25 at 4:30 p.m. Eastern Time
BOSTON, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on...
-
Feb 13, 2020
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Amber Salzman,...
-
Jan 28, 2020Favorable safety and tolerability were observed
BOSTON and CARLSBAD, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Jan 22, 2020Favorable safety and tolerability were demonstrated in hypertriglyceridemia patients in the study
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from...
-
Jan 10, 2020
BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Jan 2, 2020Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile
BOSTON and CARLSBAD, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Dec 18, 2019Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020
BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Dec 16, 2019Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board
BOSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointments of Lynne Parshall,...
Dec 4, 2019Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience in the biopharmaceutical sectorBOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the...
-
Nov 25, 2019
BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Nov 19, 2019
BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Nov 13, 2019
BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to...
-
Nov 5, 2019Reported Third Quarter 2019 Global Net Product Revenues of $12 Million
BOSTON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to...
-
Nov 1, 2019Approval and launch of WAYLIVRA® (volanesorsen) in Europe, the only treatment option for FCS patients, highlights progress in clinical research
BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today recognizes Familial...
